
1. j trop med hyg. 2011 apr;84(4):532-4. doi: 10.4269/ajtmh.2011.10-0486.

therapeutic efficacy chloroquine plasmodium vivax pvmdr1
polymorphisms republic korea mass chemoprophylaxis.

kim yk(1), kim c, park i, kim hy, choi jy, kim jm.

author information: 
(1)department internal medicine, yonsei university, wonju college medicine,
wonju, kangwon-do, republic korea. amoxj@yonsei.ac.kr

chemoprophylaxis hydroxychloroquine (hcq) primaquine used in
the republic korea (rok) army since 1997. may facilitate development of
chloroquine (cq)-resistant strains plasmodium vivax. investigated the
therapeutic efficacy hcq pvmdr1 gene polymorphisms p. vivax. from
june september 2006, 102 soldiers vivax malaria near demilitarized
zone gyeonggi-do, rok, enrolled study. determined status of
compliance chemoprophylaxis. 85 patients, therapeutic efficacy was
monitored 28 days standard hcq treatment; 66 (64.7%) 102 malaria
patients taken chemoprolaxis hcq. patients enrolled the
therapeutic efficacy monitoring, parasitemia observed since 3 days
after standard hcq treatment. however, ubiquitous presence f1076l
mutation pvmdr1 observed. evidence f1076l
mutation pvmdr1 could contribute failure hcq treatment.

doi: 10.4269/ajtmh.2011.10-0486 
pmcid: pmc3062443
pmid: 21460004  [indexed medline]

